Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tolmar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolmar Publishes FENSOLVI \u00ae for Injectable Suspension Safety and Efficacy Data in Journal of Clinical Endocrinology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Recordati","pharmaFlowCategory":"D","amount":"$168.6 million","upfrontCash":"$42.1 million","newsHeadline":"Recordati: License Obtained for the Commercialization of Eligard in Europe and Other Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolmar Publishes Study on the Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Returns Rights to EligardTM in Europe, Middle East, CIS, and Asia to Tolmar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Tolmar","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tolmar Announces Acquisition of JATENZO\u00ae (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by TOLMAR INC

    Menu

    TOLMAR INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tolmar

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tolmar Announces Acquisition of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio

              Details:

              Following a competitive auction process, Tolmar was selected as the winning bidder in the sale of JATENZO (testosterone undecanoate), and the sale was approved by the U.S. Bankruptcy Court for the District of Delaware.

              Lead Product(s): Testosterone Undecanoate

              Therapeutic Area: Endocrinology Product Name: Jatenzo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Clarus Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition October 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®

              Details:

              Under terms of the agreement, Tolmar’s sales force will promote ALKINDI SPRINKLE® to their pediatric endocrinology targets alongside FENSOLVI®. ALKINDI SPRINKLE® (hydrocortisone) oral granules is FDA-approved as replacement therapy for Adrenocortical Insufficiency (AI).

              Lead Product(s): Hydrocortisone

              Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eton Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD in Canada

              Details:

              Throughout the transition, Sanofi Canada and Tolmar are collaborating fully to help ensure smooth transfer of the product and services for patients and healthcare providers, including the ELIGARD® Home Injection Program in place in Canada.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Oncology Product Name: Eligard

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tolmar Publishes Study on the Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations

              Details:

              The Company's lead product, ELIGARD®, is a luteinizing hormone releasing hormone (LHRH) agonist indicated for the treatment of advanced prostate cancer.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Endocrinology Product Name: Eligard

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Astellas Returns Rights to EligardTM in Europe, Middle East, CIS, and Asia to Tolmar

              Details:

              Astellas Europe will return the in-licensing rights to “Eligard (leuprolide acetate for injectable suspension)” a treatment for advanced prostate cancer sold by Astellas Europe in Europe, the Middle East, the Commonwealth of Independent States (CIS)1 , and Asia, to Tolmar.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Oncology Product Name: Eligard

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Astellas Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Recordati: License Obtained for the Commercialization of Eligard in Europe and Other Countries

              Details:

              Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Oncology Product Name: Eligard

              Highest Development Status: Approved Product Type: Peptide

              Recipient: Recordati

              Deal Size: $168.6 million Upfront Cash: $42.1 million

              Deal Type: Licensing Agreement January 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tolmar

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tolmar Publishes FENSOLVI ® for Injectable Suspension Safety and Efficacy Data in Journal of Clinical Endocrinology and Metabolism

              Details:

              The study evaluated 45-mg subcutaneous leuprolide acetate administered at a 6-month interval in 64 GnRHa-naïve children with CPP. Fensolvi effectively suppressed reproductive hormones and stopped or caused regression of pubertal progression.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Endocrinology Product Name: Fensolvi

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY